Showing results (401-410 of 426) with videos related to

Sort By:
Pageof 43
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 16, 2026
Interplay between genetic ancestry, self-reported race and ethnicity, and clinical factors in pediatric acute lymphoblastic leukemia: A REDIAL Consortium ReportPragati Kore, Jennifer M Geris, Maria Leon-Camarena, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
Nature Genetics|September 18, 2025
Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effectsKonrad J Karczewski, Rahul Gupta, Masahiro Kanai, et al.
JAMA Network Open|October 9, 2024
Psychological Distress Among Ethnically Diverse Participants From Eastern and Southern AfricaKester B B Tindi, Allan Kalungi, Eugene Kinyanda, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
Pageof 43